Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Nephropathy Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TENC1/TNS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TENC1/TNS2 Recombinant Protein (SH2/PTB Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View TNS2 Products |
| Gene Delivery | TENC1/TNS2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic rescue assays. |
View TNS2 Products |
| Benchmark Ab | Anti-TENC1/TNS2 Recombinant Antibody Recombinant positive control validated for Western Blot, Immunoprecipitation, and IHC. |
View TNS2 Products |
| Validator | TENC1/TNS2 siRNA Set For specific knockdown verification in functional assays. |
View TNS2 Products |
| Related Target A | DLC1 (Deleted in Liver Cancer 1) Direct binding partner of TNS2; essential for focal adhesion localization and tumor suppressive activity. |
View DLC1 Products |
| Related Target B | ITGB1 (Integrin Beta-1) Upstream receptor anchoring focal adhesion complexes regulated by TNS2. |
View ITGB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) Screening | Truncated SH2 and PTB domain-specific proteins available with high purity (>95%) and biotinylation options. |
| Homolog Off-Target Counter-screening | Tensin family panel (TNS1, TNS3, TNS4) strictly verified by Mass Spectrometry to evaluate compound selectivity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-affinity positive control antibodies included. |
| False Positives in Phenotypic Screens | Highly validated siRNA sets included for target-specific knockdown verification. |
Live TENC1/TNS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TENC1/TNS2 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to mechanotransduction-related focal adhesion proteins. TENC1/TNS2 (Tensin-2) acts as a critical bridge linking the extracellular matrix to the actin cytoskeleton, regulating cell migration, proliferation, and survival. As first-generation therapies targeting focal adhesion kinase (FAK) reach the clinic, the next wave of R&D is targeting downstream intracellular adapters like TNS2 to bypass resistance and achieve tissue-specific modulation.
In oncology, TNS2 functions as a contextual tumor suppressor or oncogenic driver. Its interaction with DLC1 (Deleted in Liver Cancer 1) is a major focus for small molecule PPI (Protein-Protein Interaction) stabilizers designed to suppress metastasis. Conversely, in nephrology, mutations or loss of TNS2 lead to podocyte hypertrophy and nephrotic syndrome, positioning TNS2 gene therapy and mRNA-based rescue therapies as highly promising avenues for renal disease treatment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors / Stabilizers | Academic Consortia, Emerging Biotechs | Hepatocellular Carcinoma, NSCLC, Solid Tumors | Protein-Protein Interaction Assay (Requires biotinylated TNS2 SH2/PTB domains) |
| PROTACs (Degraders) | Targeted Protein Degradation (TPD) Pioneers | Metastatic Cancers, Fibrotic Diseases | Binding Affinity & Degradation Kinetics (Requires high-purity full-length TNS2) |
| Gene Therapy (Lentivirus/AAV) | Rare Disease Therapeutics, Nephrology Startups | Nephrotic Syndrome, Podocytopathy | Cellular Phenotypic Rescue (Requires high-titer Lentivirus for stable expression) |